Microhaem Scientifics (MHS) was honored to host the senior leadership of Equity Bank Kenya and Equity Bank Uganda for a high-level courtesy engagement and strategic progress review of MHS’s large-scale In-Vitro Diagnostics (IVD) manufacturing operations and expansion.
The delegation was led by Mr. Moses Nyabanda, Managing Director, Equity Bank Kenya, and Mr. Claver Serumaga, Executive Director, Equity Bank Uganda, alongside other senior Equity Group representatives. The engagement served as a structured progress check-in aligned with Equity Group’s strategic support for MHS’s manufacturing scale-up.
Discussions focused on:
- Reviewing progress and performance milestones across current IVD manufacturing operations
- Assessing strategic pathways to significantly expand production capacity and operational efficiency
- Reaffirming alignment on strengthening Africa’s health sovereignty through high-quality, locally manufactured diagnostic solutions
The engagement reaffirmed the strength of the public–private partnership underpinning MHS’s growth strategy and its role in advancing local manufacturing of affordable, WHO-aligned diagnostic products for HIV, malaria, sickle cell disease, hepatitis, HPV, and other priority conditions. This approach supports reduced import dependence, cost containment, skilled job creation, and long-term health system resilience across the region.
Microhaem Scientifics extends its appreciation to the Equity Group senior leadership for their confidence, strategic partnership, and sustained commitment to homegrown innovation that delivers measurable public health impact. The Group’s continued engagement reflects sustained assurance in MHS’s strategic direction, operational execution, and long-term value proposition within Africa’s health manufacturing ecosystem.
